Canadas Big Tobacco Settlement Falls Short: Provinces Face a Massive Financial Gap in Covering Tobacco-Related Costs, Says National Lung Health Alliance
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- The National Lung Health Alliance…
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
DURHAM, NC and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging…
National Non-Smoking Week: A Call to Breathe Easier by Starting the Quit Journey with Lung Health Foundation
TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- This week, Canadians from coast…
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Application based on TROPION-Lung05 phase 2 trial and supported by data from…
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
MIAMI--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that…
PureTechs Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
Merus Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NonSmall Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
BIZENGRI® is the first and only therapy approved by the FDA specifically…